Proteostasis Therapeutics announced an R&D and commercialization pharma deal with Tokyo-based Astellas Pharma.
The focus of the agreement will be to research and develop compounds that modulate the Unfolded Protein Response (UPR) through the use of Proteostasis’s proprietary “Disease Relevant Translation” and “Proteostasis Network” platform.
The research will focus on a single genetic disease, then spread out to additional conditions that are affected by modulation of the UPR pathway.
A number of genetic diseases, neurodegenerative and retinal degenerative diseases are related to unfolded proteins in the endoplasmic reticulum (ER).
In non-clinical studies, selective modulation of the UPR pathway has improved stressresponse and restored function.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity